Jeito Capital — 2022 Investments

2 investments dated 2022 · listed companies and verified rows first · show all

HI-Biohibio.comNov 2022acquired by Biogen

Biotech company developing antibodies to treat autoimmune and inflammatory diseases.

Co-investorsAlpha Wave Global Arkin Capital Arkin Digital Health Monograph Capital Partners Viking Global ARCH Venture Partners +1 more

Pulmocidepulmocide.com inDec 2022 · $52M

Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis.

BiotechHealthtech

Pete Strong(Co-founder)Garth Rapeport(Co-founder)inKazuhiro Ito(Co-founder)inJohn Murray(Co-founder)inDavid Mantusin

Co-investorsAdjuvant Capital Asahi Kasei Corporate Venture Capital Dementia Discovery Fund F-Prime Capital Longwood Fund SR One Capital Management +4 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.